{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:36:08Z","timestamp":1790314568144,"version":"4.1.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR069660"],"award-info":[{"award-number":["AR069660"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The limb-girdle muscular dystrophies (LGMDs) are a genetically pleiomorphic class of inherited muscle diseases that are known to share phenotypic features. Selected LGMD genetic subtypes have been studied extensively in affected humans and various animal models. In some cases, these investigations have led to human clinical trials of potential disease-modifying therapies, including gene replacement strategies for individual subtypes using adeno-associated virus (AAV) vectors. The cellular localizations of most proteins associated with LGMD have been determined. However, the functions of these proteins are less uniformly characterized, thus limiting our knowledge of potential common disease mechanisms across subtype boundaries. Correspondingly, broad therapeutic strategies that could each target multiple LGMD subtypes remain less developed. We believe that three major \u201cfunctional clusters\u201d of subcellular activities relevant to LGMD merit further investigation. The best known of these is the glycosylation modifications associated with the dystroglycan complex. The other two, mechanical signaling and mitochondrial dysfunction, have been studied less systematically but are just as promising with respect to the identification of significant mechanistic subgroups of LGMD. A deeper understanding of these disease pathways could yield a new generation of precision therapies that would each be expected to treat a broader range of LGMD patients than a single subtype, thus expanding the scope of the molecular medicines that may be developed for this complex array of muscular dystrophies.<\/jats:p>","DOI":"10.1186\/s13395-020-00240-7","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T05:26:52Z","timestamp":1596000412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The ties that bind: functional clusters in limb-girdle muscular dystrophy"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-4398","authenticated-orcid":false,"given":"Elisabeth R.","family":"Barton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney L.","family":"Stoppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"240_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/323646a0","volume":"323","author":"AP Monaco","year":"1986","unstructured":"Monaco AP, et al. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986;323:646\u201350. https:\/\/doi.org\/10.1038\/323646a0.","journal-title":"Nature"},{"key":"240_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4.","journal-title":"Cell"},{"key":"240_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"key":"240_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3.","journal-title":"Orphanet J Rare Dis"},{"key":"240_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000110905","volume":"11","author":"ML Mostacciuolo","year":"1992","unstructured":"Mostacciuolo ML, Danieli GA, Trevisan C, Muller E, Angelini C. Epidemiology of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology. 1992;11:34\u20138. https:\/\/doi.org\/10.1159\/000110905.","journal-title":"Neuroepidemiology"},{"key":"240_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264:1465\u201373. https:\/\/doi.org\/10.1007\/s00415-017-8549-1.","journal-title":"J Neurol"},{"key":"240_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2019.07.018","volume":"102","author":"CA Pacak","year":"2020","unstructured":"Pacak CA, Kang PB. The end of the beginning: the journey to molecular therapies for spinal muscular atrophy. Pediatr Neurol. 2020;102:1\u20132. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.07.018.","journal-title":"Pediatr Neurol"},{"key":"240_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes LP, et al. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.05.005.","journal-title":"Pediatr Neurol"},{"key":"240_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/cjn.2015.311","volume":"43","author":"JK Mah","year":"2016","unstructured":"Mah JK, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43:163\u201377. https:\/\/doi.org\/10.1017\/cjn.2015.311.","journal-title":"Can J Neurol Sci"},{"key":"240_CR10","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FL Norwood","year":"2009","unstructured":"Norwood FL, et al. Prevalence of genetic muscle disease in northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175\u201386. https:\/\/doi.org\/10.1093\/brain\/awp236.","journal-title":"Brain"},{"key":"240_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bdr2.1371","volume":"110","author":"TN Do","year":"2018","unstructured":"Do TN, et al. Muscular dystrophy surveillance, tracking, and research network pilot: population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011. Birth Defects Res. 2018;110:1404\u201311. https:\/\/doi.org\/10.1002\/bdr2.1371.","journal-title":"Birth Defects Res"},{"key":"240_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12883-015-0449-3","volume":"15","author":"JA Petersen","year":"2015","unstructured":"Petersen JA, et al. Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects. BMC Neurol. 2015;15:182. https:\/\/doi.org\/10.1186\/s12883-015-0449-3.","journal-title":"BMC Neurol"},{"key":"240_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.nmd.2018.05.007","volume":"28","author":"V Straub","year":"2018","unstructured":"Straub V, Murphy A, Udd B, LGMD Workshop Study Group. 229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 march 2017. Neuromuscul Disord. 2018;28:702\u201310. https:\/\/doi.org\/10.1016\/j.nmd.2018.05.007.","journal-title":"Neuromuscul Disord"},{"key":"240_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0092-8674(95)90368-2","volume":"81","author":"I Richard","year":"1995","unstructured":"Richard I, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81:27\u201340. https:\/\/doi.org\/10.1016\/0092-8674(95)90368-2.","journal-title":"Cell"},{"key":"240_CR15","doi-asserted-by":"publisher","first-page":"31158","DOI":"10.1074\/jbc.270.52.31158","volume":"270","author":"H Sorimachi","year":"1995","unstructured":"Sorimachi H, et al. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem. 1995;270:31158\u201362. https:\/\/doi.org\/10.1074\/jbc.270.52.31158.","journal-title":"J Biol Chem"},{"key":"240_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/1689","volume":"20","author":"R Bashir","year":"1998","unstructured":"Bashir R, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998;20:37\u201342. https:\/\/doi.org\/10.1038\/1689.","journal-title":"Nat Genet"},{"key":"240_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/1682","volume":"20","author":"J Liu","year":"1998","unstructured":"Liu J, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20:31\u20136. https:\/\/doi.org\/10.1038\/1682.","journal-title":"Nat Genet"},{"key":"240_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature01573","volume":"423","author":"D Bansal","year":"2003","unstructured":"Bansal D, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168\u201372. https:\/\/doi.org\/10.1038\/nature01573.","journal-title":"Nature"},{"key":"240_CR19","doi-asserted-by":"publisher","first-page":"50466","DOI":"10.1074\/jbc.M307247200","volume":"278","author":"NJ Lennon","year":"2003","unstructured":"Lennon NJ, et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003;278:50466\u201373. https:\/\/doi.org\/10.1074\/jbc.M307247200.","journal-title":"J Biol Chem"},{"key":"240_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/ng0695-243","volume":"10","author":"F Piccolo","year":"1995","unstructured":"Piccolo F, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet. 1995;10:243\u20135. https:\/\/doi.org\/10.1038\/ng0695-243.","journal-title":"Nat Genet"},{"key":"240_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ng1195-266","volume":"11","author":"CG Bonnemann","year":"1995","unstructured":"Bonnemann CG, et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet. 1995;11:266\u201373. https:\/\/doi.org\/10.1038\/ng1195-266.","journal-title":"Nat Genet"},{"key":"240_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng1195-257","volume":"11","author":"LE Lim","year":"1995","unstructured":"Lim LE, et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet. 1995;11:257\u201365. https:\/\/doi.org\/10.1038\/ng1195-257.","journal-title":"Nat Genet"},{"key":"240_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.270.5237.819","volume":"270","author":"S Noguchi","year":"1995","unstructured":"Noguchi S, et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science. 1995;270:819\u201322. https:\/\/doi.org\/10.1126\/science.270.5237.819.","journal-title":"Science"},{"key":"240_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ng1096-195","volume":"14","author":"V Nigro","year":"1996","unstructured":"Nigro V, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet. 1996;14:195\u20138. https:\/\/doi.org\/10.1038\/ng1096-195.","journal-title":"Nat Genet"},{"key":"240_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/72822","volume":"24","author":"ES Moreira","year":"2000","unstructured":"Moreira ES, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet. 2000;24:163\u20136. https:\/\/doi.org\/10.1038\/72822.","journal-title":"Nat Genet"},{"key":"240_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/dvdy.22263","volume":"239","author":"T Sadikot","year":"2010","unstructured":"Sadikot T, Hammond CR, Ferrari MB. Distinct roles for telethonin N-versus C-terminus in sarcomere assembly and maintenance. Dev Dyn. 2010;239:1124\u201335. https:\/\/doi.org\/10.1002\/dvdy.22263.","journal-title":"Dev Dyn"},{"key":"240_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1086\/339083","volume":"70","author":"P Frosk","year":"2002","unstructured":"Frosk P, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet. 2002;70:663\u201372. https:\/\/doi.org\/10.1086\/339083.","journal-title":"Am J Hum Genet"},{"key":"240_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2005.09.068","volume":"354","author":"E Kudryashova","year":"2005","unstructured":"Kudryashova E, Kudryashov D, Kramerova I, Spencer MJ. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J Mol Biol. 2005;354:413\u201324. https:\/\/doi.org\/10.1016\/j.jmb.2005.09.068.","journal-title":"J Mol Biol"},{"key":"240_CR29","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/10.25.2851","volume":"10","author":"M Brockington","year":"2001","unstructured":"Brockington M, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet. 2001;10:2851\u20139. https:\/\/doi.org\/10.1093\/hmg\/10.25.2851.","journal-title":"Hum Mol Genet"},{"key":"240_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/342380","volume":"71","author":"P Hackman","year":"2002","unstructured":"Hackman P, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet. 2002;71:492\u2013500. https:\/\/doi.org\/10.1086\/342380.","journal-title":"Am J Hum Genet"},{"key":"240_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1083\/jcb.126.5.1201","volume":"126","author":"KJ Eilertsen","year":"1994","unstructured":"Eilertsen KJ, Kazmierski ST, Keller TC 3rd. Cellular titin localization in stress fibers and interaction with myosin II filaments in vitro. J Cell Biol. 1994;126:1201\u201310. https:\/\/doi.org\/10.1083\/jcb.126.5.1201.","journal-title":"J Cell Biol"},{"key":"240_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nmd.2005.01.013","volume":"15","author":"B Balci","year":"2005","unstructured":"Balci B, et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord. 2005;15:271\u20135. https:\/\/doi.org\/10.1016\/j.nmd.2005.01.013.","journal-title":"Neuromuscul Disord"},{"key":"240_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajhg.2009.12.013","volume":"86","author":"V Bolduc","year":"2010","unstructured":"Bolduc V, et al. Recessive mutations in the putative calcium-activated chloride channel anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet. 2010;86:213\u201321. https:\/\/doi.org\/10.1016\/j.ajhg.2009.12.013.","journal-title":"Am J Hum Genet"},{"key":"240_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.20973","volume":"60","author":"T Murakami","year":"2006","unstructured":"Murakami T, et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol. 2006;60:597\u2013602. https:\/\/doi.org\/10.1002\/ana.20973.","journal-title":"Ann Neurol"},{"key":"240_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ana.21006","volume":"60","author":"C Godfrey","year":"2006","unstructured":"Godfrey C, et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol. 2006;60:603\u201310. https:\/\/doi.org\/10.1002\/ana.21006.","journal-title":"Ann Neurol"},{"key":"240_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bbrc.2007.09.066","volume":"363","author":"R Biancheri","year":"2007","unstructured":"Biancheri R, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun. 2007;363:1033\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2007.09.066.","journal-title":"Biochem Biophys Res Commun"},{"key":"240_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archneurol.2007.2","volume":"65","author":"EM Clement","year":"2008","unstructured":"Clement EM, et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol. 2008;65:137\u201341. https:\/\/doi.org\/10.1001\/archneurol.2007.2.","journal-title":"Arch Neurol"},{"key":"240_CR38","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/brain\/awm212","volume":"130","author":"C Godfrey","year":"2007","unstructured":"Godfrey C, et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007;130:2725\u201335. https:\/\/doi.org\/10.1093\/brain\/awm212.","journal-title":"Brain"},{"key":"240_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJMoa1006939","volume":"364","author":"Y Hara","year":"2011","unstructured":"Hara Y, et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med. 2011;364:939\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1006939.","journal-title":"N Engl J Med"},{"key":"240_CR40","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1073\/pnas.1605265113","volume":"113","author":"EP Rader","year":"2016","unstructured":"Rader EP, et al. Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle. Proc Natl Acad Sci U S A. 2016;113:10992\u20137. https:\/\/doi.org\/10.1073\/pnas.1605265113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"240_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2010.10.017","volume":"87","author":"H Gundesli","year":"2010","unstructured":"Gundesli H, et al. Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy. Am J Hum Genet. 2010;87:834\u201341. https:\/\/doi.org\/10.1016\/j.ajhg.2010.10.017.","journal-title":"Am J Hum Genet"},{"key":"240_CR42","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1172\/JCI71919","volume":"124","author":"L Winter","year":"2014","unstructured":"Winter L, et al. Chemical chaperone ameliorates pathological protein aggregation in plectin-deficient muscle. J Clin Invest. 2014;124:1144\u201357. https:\/\/doi.org\/10.1172\/JCI71919.","journal-title":"J Clin Invest"},{"key":"240_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4161\/bioa.1.1.14630","volume":"1","author":"G Wiche","year":"2011","unstructured":"Wiche G, Winter L. Plectin isoforms as organizers of intermediate filament cytoarchitecture. Bioarchitecture. 2011;1:14\u201320. https:\/\/doi.org\/10.4161\/bioa.1.1.14630.","journal-title":"Bioarchitecture"},{"key":"240_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00418-013-1102-0","volume":"140","author":"MJ Castanon","year":"2013","unstructured":"Castanon MJ, Walko G, Winter L, Wiche G. Plectin-intermediate filament partnership in skin, skeletal muscle, and peripheral nerve. Histochem Cell Biol. 2013;140:33\u201353. https:\/\/doi.org\/10.1007\/s00418-013-1102-0.","journal-title":"Histochem Cell Biol"},{"key":"240_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajhg.2013.05.028","volume":"93","author":"N Bogershausen","year":"2013","unstructured":"Bogershausen N, et al. Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. Am J Hum Genet. 2013;93:181\u201390. https:\/\/doi.org\/10.1016\/j.ajhg.2013.05.028.","journal-title":"Am J Hum Genet"},{"key":"240_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajhg.2013.05.009","volume":"93","author":"KJ Carss","year":"2013","unstructured":"Carss KJ, et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan. Am J Hum Genet. 2013;93:29\u201341. https:\/\/doi.org\/10.1016\/j.ajhg.2013.05.009.","journal-title":"Am J Hum Genet"},{"key":"240_CR47","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1212\/WNL.0b013e3182840cbc","volume":"80","author":"G Tasca","year":"2013","unstructured":"Tasca G, et al. Limb-girdle muscular dystrophy with alpha-dystroglycan deficiency and mutations in the ISPD gene. Neurology. 2013;80:963\u20135. https:\/\/doi.org\/10.1212\/WNL.0b013e3182840cbc.","journal-title":"Neurology"},{"key":"240_CR48","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.15252\/emmm.201505815","volume":"8","author":"E Servian-Morilla","year":"2016","unstructured":"Servian-Morilla E, et al. A POGLUT1 mutation causes a muscular dystrophy with reduced notch signaling and satellite cell loss. EMBO Mol Med. 2016;8:1289\u2013309. https:\/\/doi.org\/10.15252\/emmm.201505815.","journal-title":"EMBO Mol Med"},{"key":"240_CR49","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/ncomms2964","volume":"4","author":"A Urciuolo","year":"2013","unstructured":"Urciuolo A, et al. Collagen VI regulates satellite cell self-renewal and muscle regeneration. Nat Commun. 2013;4:1964. https:\/\/doi.org\/10.1038\/ncomms2964.","journal-title":"Nat Commun"},{"key":"240_CR50","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/hmg\/ddq499","volume":"20","author":"V Carmignac","year":"2011","unstructured":"Carmignac V, Quere R, Durbeej M. Proteasome inhibition improves the muscle of laminin alpha2 chain-deficient mice. Hum Mol Genet. 2011;20:541\u201352. https:\/\/doi.org\/10.1093\/hmg\/ddq499.","journal-title":"Hum Mol Genet"},{"key":"240_CR51","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/hmg\/ddr427","volume":"20","author":"V Carmignac","year":"2011","unstructured":"Carmignac V, et al. Autophagy is increased in laminin alpha2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum Mol Genet. 2011;20:4891\u2013902. https:\/\/doi.org\/10.1093\/hmg\/ddr427.","journal-title":"Hum Mol Genet"},{"key":"240_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1172\/JCI79562","volume":"126","author":"RF Schindler","year":"2016","unstructured":"Schindler RF, et al. POPDC1(S201F) causes muscular dystrophy and arrhythmia by affecting protein trafficking. J Clin Invest. 2016;126:239\u201353. https:\/\/doi.org\/10.1172\/JCI79562.","journal-title":"J Clin Invest"},{"key":"240_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1152\/physiolgenomics.00036.2018","volume":"50","author":"M Saha","year":"2018","unstructured":"Saha M, et al. Impact of PYROXD1 deficiency on cellular respiration and correlations with genetic analyses of limb-girdle muscular dystrophy in Saudi Arabia and Sudan. Physiol Genomics. 2018;50:929\u201339. https:\/\/doi.org\/10.1152\/physiolgenomics.00036.2018.","journal-title":"Physiol Genomics"},{"key":"240_CR54","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00415-018-9137-8","volume":"266","author":"MT Sainio","year":"2019","unstructured":"Sainio MT, et al. Recessive PYROXD1 mutations cause adult-onset limb-girdle-type muscular dystrophy. J Neurol. 2019;266:353\u201360. https:\/\/doi.org\/10.1007\/s00415-018-9137-8.","journal-title":"J Neurol"},{"key":"240_CR55","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ajhg.2016.09.005","volume":"99","author":"GL O'Grady","year":"2016","unstructured":"O'Grady GL, et al. Variants in the oxidoreductase PYROXD1 cause early-onset myopathy with internalized nuclei and myofibrillar disorganization. Am J Hum Genet. 2016;99:1086\u2013105. https:\/\/doi.org\/10.1016\/j.ajhg.2016.09.005.","journal-title":"Am J Hum Genet"},{"issue":"450-455","key":"240_CR56","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.1038\/ng.1103","volume":"44","author":"J Sarparanta","year":"2012","unstructured":"Sarparanta J, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet. 2012;44(450-455):S451\u20132. https:\/\/doi.org\/10.1038\/ng.1103.","journal-title":"Nat Genet"},{"key":"240_CR57","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.22683","volume":"71","author":"MB Harms","year":"2012","unstructured":"Harms MB, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol. 2012;71:407\u201316. https:\/\/doi.org\/10.1002\/ana.22683.","journal-title":"Ann Neurol"},{"key":"240_CR58","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1093\/hmg\/ddv363","volume":"24","author":"R Bengoechea","year":"2015","unstructured":"Bengoechea R, Pittman SK, Tuck EP, True HL, Weihl CC. Myofibrillar disruption and RNA-binding protein aggregation in a mouse model of limb-girdle muscular dystrophy 1D. Hum Mol Genet. 2015;24:6588\u2013602. https:\/\/doi.org\/10.1093\/hmg\/ddv363.","journal-title":"Hum Mol Genet"},{"key":"240_CR59","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/brain\/awt074","volume":"136","author":"MJ Melia","year":"2013","unstructured":"Melia MJ, et al. Limb-girdle muscular dystrophy 1F is caused by a microdeletion in the transportin 3 gene. Brain. 2013;136:1508\u201317. https:\/\/doi.org\/10.1093\/brain\/awt074.","journal-title":"Brain"},{"key":"240_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063536","volume":"8","author":"A Torella","year":"2013","unstructured":"Torella A, et al. Next-generation sequencing identifies transportin 3 as the causative gene for LGMD1F. PLoS One. 2013;8:e63536. https:\/\/doi.org\/10.1371\/journal.pone.0063536.","journal-title":"PLoS One"},{"key":"240_CR61","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1074\/jbc.275.11.7950","volume":"275","author":"MC Lai","year":"2000","unstructured":"Lai MC, Lin RI, Huang SY, Tsai CW, Tarn WY. A human importin-beta family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins. J Biol Chem. 2000;275:7950\u20137. https:\/\/doi.org\/10.1074\/jbc.275.11.7950.","journal-title":"J Biol Chem"},{"key":"240_CR62","doi-asserted-by":"publisher","first-page":"10154","DOI":"10.1073\/pnas.181354098","volume":"98","author":"MC Lai","year":"2001","unstructured":"Lai MC, Lin RI, Tarn WY. Transportin-SR2 mediates nuclear import of phosphorylated SR proteins. Proc Natl Acad Sci U S A. 2001;98:10154\u20139. https:\/\/doi.org\/10.1073\/pnas.181354098.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"240_CR63","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1093\/hmg\/ddu127","volume":"23","author":"NM Vieira","year":"2014","unstructured":"Vieira NM, et al. A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G). Hum Mol Genet. 2014;23:4103\u201310. https:\/\/doi.org\/10.1093\/hmg\/ddu127.","journal-title":"Hum Mol Genet"},{"key":"240_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.25192","volume":"55","author":"F Magri","year":"2017","unstructured":"Magri F, et al. The Italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve. 2017;55:55\u201368. https:\/\/doi.org\/10.1002\/mus.25192.","journal-title":"Muscle Nerve"},{"key":"240_CR65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/humu.20642","volume":"29","author":"M Guglieri","year":"2008","unstructured":"Guglieri M, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat. 2008;29:258\u201366. https:\/\/doi.org\/10.1002\/humu.20642.","journal-title":"Hum Mutat"},{"key":"240_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170280","volume":"12","author":"CA Pantoja-Melendez","year":"2017","unstructured":"Pantoja-Melendez CA, Miranda-Duarte A, Roque-Ramirez B, Zenteno JC. Epidemiological and molecular characterization of a Mexican population isolate with high prevalence of limb-girdle muscular dystrophy type 2A due to a novel calpain-3 mutation. PLoS One. 2017;12:e0170280. https:\/\/doi.org\/10.1371\/journal.pone.0170280.","journal-title":"PLoS One"},{"key":"240_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/gtmb.2013.0326","volume":"18","author":"F El Kerch","year":"2014","unstructured":"El Kerch F, et al. Carrier frequency of the c.525delT mutation in the SGCG gene and estimated prevalence of limb girdle muscular dystrophy type 2C among the Moroccan population. Genet Test Mol Biomarkers. 2014;18:253\u20136. https:\/\/doi.org\/10.1089\/gtmb.2013.0326.","journal-title":"Genet Test Mol Biomarkers"},{"key":"240_CR68","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mus.25094","volume":"54","author":"HM Reddy","year":"2016","unstructured":"Reddy HM, et al. Homozygous nonsense mutation in SGCA is a common cause of limb-girdle muscular dystrophy in Assiut, Egypt. Muscle Nerve. 2016;54:690\u20135. https:\/\/doi.org\/10.1002\/mus.25094.","journal-title":"Muscle Nerve"},{"key":"240_CR69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/mus.23763","volume":"47","author":"A Ankala","year":"2013","unstructured":"Ankala A, et al. Ancestral founder mutations in calpain-3 in the Indian Agarwal community: historical, clinical, and molecular perspective. Muscle Nerve. 2013;47:931\u20137. https:\/\/doi.org\/10.1002\/mus.23763.","journal-title":"Muscle Nerve"},{"key":"240_CR70","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/brain\/awq294","volume":"134","author":"D Hicks","year":"2011","unstructured":"Hicks D, et al. A founder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain. 2011;134:171\u201382. https:\/\/doi.org\/10.1093\/brain\/awq294.","journal-title":"Brain"},{"key":"240_CR71","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/jhg.2010.60","volume":"55","author":"R Santos","year":"2010","unstructured":"Santos R, et al. Private dysferlin exon skipping mutation (c.5492G>a) with a founder effect reveals further alternative splicing involving exons 49-51. J Hum Genet. 2010;55:546\u20139. https:\/\/doi.org\/10.1038\/jhg.2010.60.","journal-title":"J Hum Genet"},{"key":"240_CR72","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.nmd.2007.07.010","volume":"17","author":"E Leshinsky-Silver","year":"2007","unstructured":"Leshinsky-Silver E, et al. Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene. Neuromuscul Disord. 2007;17:950\u20134. https:\/\/doi.org\/10.1016\/j.nmd.2007.07.010.","journal-title":"Neuromuscul Disord"},{"key":"240_CR73","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/archneur.62.8.1256","volume":"62","author":"JJ Vilchez","year":"2005","unstructured":"Vilchez JJ, et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol. 2005;62:1256\u20139. https:\/\/doi.org\/10.1001\/archneur.62.8.1256.","journal-title":"Arch Neurol"},{"key":"240_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/humu.20110","volume":"25","author":"P Frosk","year":"2005","unstructured":"Frosk P, et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat. 2005;25:38\u201344. https:\/\/doi.org\/10.1002\/humu.20110.","journal-title":"Hum Mutat"},{"key":"240_CR75","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ajmg.a.20408","volume":"125A","author":"N Canki-Klain","year":"2004","unstructured":"Canki-Klain N, et al. Prevalence of the 550delA mutation in calpainopathy (LGMD 2A) in Croatia. Am J Med Genet A. 2004;125A:152\u20136. https:\/\/doi.org\/10.1002\/ajmg.a.20408.","journal-title":"Am J Med Genet A"},{"key":"240_CR76","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1212\/wnl.54.5.1075","volume":"54","author":"L Merlini","year":"2000","unstructured":"Merlini L, et al. Homogeneous phenotype of the gypsy limb-girdle MD with the gamma-sarcoglycan C283Y mutation. Neurology. 2000;54:1075\u20139. https:\/\/doi.org\/10.1212\/wnl.54.5.1075.","journal-title":"Neurology"},{"key":"240_CR77","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.ejhg.5200197","volume":"6","author":"A Lasa","year":"1998","unstructured":"Lasa A, et al. Severe limb girdle muscular dystrophy in Spanish gypsies: further evidence for a founder mutation in the gamma-sarcoglycan gene. Eur J Hum Genet. 1998;6:396\u20139. https:\/\/doi.org\/10.1038\/sj.ejhg.5200197.","journal-title":"Eur J Hum Genet"},{"issue":"Pt 9","key":"240_CR78","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/brain\/121.9.1735","volume":"121","author":"M Urtasun","year":"1998","unstructured":"Urtasun M, et al. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain. 1998;121(Pt 9):1735\u201347. https:\/\/doi.org\/10.1093\/brain\/121.9.1735.","journal-title":"Brain"},{"key":"240_CR79","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/mgg3.125","volume":"3","author":"SA Al-Zaidy","year":"2015","unstructured":"Al-Zaidy SA, et al. A slowly progressive form of limb-girdle muscular dystrophy type 2C associated with founder mutation in the SGCG gene in Puerto Rican Hispanics. Mol Genet Genomic Med. 2015;3:92\u20138. https:\/\/doi.org\/10.1002\/mgg3.125.","journal-title":"Mol Genet Genomic Med"},{"key":"240_CR80","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24303","volume":"77","author":"A Ankala","year":"2015","unstructured":"Ankala A, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol. 2015;77:206\u201314. https:\/\/doi.org\/10.1002\/ana.24303.","journal-title":"Ann Neurol"},{"key":"240_CR81","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/acn3.649","volume":"5","author":"BRR Nallamilli","year":"2018","unstructured":"Nallamilli BRR, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018;5:1574\u201387. https:\/\/doi.org\/10.1002\/acn3.649.","journal-title":"Ann Clin Transl Neurol"},{"key":"240_CR82","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamaneurol.2015.2274","volume":"72","author":"R Ghaoui","year":"2015","unstructured":"Ghaoui R, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. JAMA Neurol. 2015;72:1424\u201332. https:\/\/doi.org\/10.1001\/jamaneurol.2015.2274.","journal-title":"JAMA Neurol"},{"key":"240_CR83","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/jhg.2016.116","volume":"62","author":"HM Reddy","year":"2017","unstructured":"Reddy HM, et al. The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. J Hum Genet. 2017;62:243\u201352. https:\/\/doi.org\/10.1038\/jhg.2016.116.","journal-title":"J Hum Genet"},{"key":"240_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymthe.2005.09.017","volume":"13","author":"M Bartoli","year":"2006","unstructured":"Bartoli M, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther. 2006;13:250\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2005.09.017.","journal-title":"Mol Ther"},{"key":"240_CR85","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.113.001340","volume":"128","author":"C Roudaut","year":"2013","unstructured":"Roudaut C, et al. Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation. 2013;128:1094\u2013104. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001340.","journal-title":"Circulation"},{"key":"240_CR86","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/hmg\/ddq065","volume":"19","author":"W Lostal","year":"2010","unstructured":"Lostal W, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet. 2010;19:1897\u2013907. https:\/\/doi.org\/10.1093\/hmg\/ddq065.","journal-title":"Hum Mol Genet"},{"key":"240_CR87","doi-asserted-by":"publisher","first-page":"50ra69","DOI":"10.1126\/scitranslmed.3000951","volume":"2","author":"M Krahn","year":"2010","unstructured":"Krahn M, et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med. 2010;2:50ra69. https:\/\/doi.org\/10.1126\/scitranslmed.3000951.","journal-title":"Sci Transl Med"},{"key":"240_CR88","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ymthe.2017.05.013","volume":"25","author":"T Llanga","year":"2017","unstructured":"Llanga T, et al. Structure-based designed nano-dysferlin significantly improves dysferlinopathy in BLA\/J mice. Mol Ther. 2017;25:2150\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.013.","journal-title":"Mol Ther"},{"key":"240_CR89","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/hum.2017.062","volume":"29","author":"RA Potter","year":"2018","unstructured":"Potter RA, et al. Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther. 2018;29:749\u201362. https:\/\/doi.org\/10.1089\/hum.2017.062.","journal-title":"Hum Gene Ther"},{"key":"240_CR90","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/mt.2013.156","volume":"21","author":"L Xu","year":"2013","unstructured":"Xu L, et al. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha-dystroglycan and improves muscle functions. Mol Ther. 2013;21:1832\u201340. https:\/\/doi.org\/10.1038\/mt.2013.156.","journal-title":"Mol Ther"},{"key":"240_CR91","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1038\/mt.2014.141","volume":"22","author":"C Qiao","year":"2014","unstructured":"Qiao C, et al. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Mol Ther. 2014;22:1890\u20139. https:\/\/doi.org\/10.1038\/mt.2014.141.","journal-title":"Mol Ther"},{"key":"240_CR92","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1093\/hmg\/ddx066","volume":"26","author":"E Gicquel","year":"2017","unstructured":"Gicquel E, et al. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Hum Mol Genet. 2017;26:1952\u201365. https:\/\/doi.org\/10.1093\/hmg\/ddx066.","journal-title":"Hum Mol Genet"},{"key":"240_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omtm.2017.02.002","volume":"5","author":"CH Vannoy","year":"2017","unstructured":"Vannoy CH, Xiao W, Lu P, Xiao X, Lu QL. Efficacy of gene therapy is dependent on disease progression in dystrophic mice with mutations in the FKRP gene. Mol Ther Methods Clin Dev. 2017;5:31\u201342. https:\/\/doi.org\/10.1016\/j.omtm.2017.02.002.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"240_CR94","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/sj.mt.6300246","volume":"15","author":"CA Pacak","year":"2007","unstructured":"Pacak CA, et al. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther. 2007;15:1775\u201381. https:\/\/doi.org\/10.1038\/sj.mt.6300246.","journal-title":"Mol Ther"},{"key":"240_CR95","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1089\/10430340260201725","volume":"13","author":"D Dressman","year":"2002","unstructured":"Dressman D, et al. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther. 2002;13:1631\u201346. https:\/\/doi.org\/10.1089\/10430340260201725.","journal-title":"Hum Gene Ther"},{"key":"240_CR96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/01.wnl.0000306309.85301.e2","volume":"71","author":"LR Rodino-Klapac","year":"2008","unstructured":"Rodino-Klapac LR, Lee JS, Mulligan RC, Clark KR, Mendell JR. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology. 2008;71:240\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000306309.85301.e2.","journal-title":"Neurology"},{"key":"240_CR97","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1089\/hum.2007.184","volume":"19","author":"A Nishiyama","year":"2008","unstructured":"Nishiyama A, et al. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice. Hum Gene Ther. 2008;19:719\u201330. https:\/\/doi.org\/10.1089\/hum.2007.184.","journal-title":"Hum Gene Ther"},{"key":"240_CR98","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ana.21732","volume":"66","author":"JR Mendell","year":"2009","unstructured":"Mendell JR, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 2009;66:290\u20137. https:\/\/doi.org\/10.1002\/ana.21732.","journal-title":"Ann Neurol"},{"key":"240_CR99","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ana.22251","volume":"68","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010;68:629\u201338. https:\/\/doi.org\/10.1002\/ana.22251.","journal-title":"Ann Neurol"},{"key":"240_CR100","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1089\/hum.2019.006","volume":"30","author":"JR Mendell","year":"2019","unstructured":"Mendell JR, et al. Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion. Hum Gene Ther. 2019;30:794\u2013801. https:\/\/doi.org\/10.1089\/hum.2019.006.","journal-title":"Hum Gene Ther"},{"key":"240_CR101","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","volume":"25","author":"ER Pozsgai","year":"2017","unstructured":"Pozsgai ER, Griffin DA, Heller KN, Mendell JR, Rodino-Klapac LR. Systemic AAV-mediated beta-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice. Mol Ther. 2017;25:855\u201369. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.013.","journal-title":"Mol Ther"},{"key":"240_CR102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/gt.2015.80","volume":"23","author":"ER Pozsgai","year":"2016","unstructured":"Pozsgai ER, Griffin DA, Heller KN, Mendell JR, Rodino-Klapac LR. Beta-sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice. Gene Ther. 2016;23:57\u201366. https:\/\/doi.org\/10.1038\/gt.2015.80.","journal-title":"Gene Ther"},{"key":"240_CR103","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/7439","volume":"5","author":"JP Greelish","year":"1999","unstructured":"Greelish JP, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999;5:439\u201343. https:\/\/doi.org\/10.1038\/7439.","journal-title":"Nat Med"},{"key":"240_CR104","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/sj.gt.3300830","volume":"6","author":"J Li","year":"1999","unstructured":"Li J, et al. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther. 1999;6:74\u201382. https:\/\/doi.org\/10.1038\/sj.gt.3300830.","journal-title":"Gene Ther"},{"key":"240_CR105","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1128\/jvi.74.3.1436-1442.2000","volume":"74","author":"X Xiao","year":"2000","unstructured":"Xiao X, et al. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol. 2000;74:1436\u201342. https:\/\/doi.org\/10.1128\/jvi.74.3.1436-1442.2000.","journal-title":"J Virol"},{"key":"240_CR106","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1006\/mthe.1999.0019","volume":"1","author":"L Cordier","year":"2000","unstructured":"Cordier L, et al. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther. 2000;1:119\u201329. https:\/\/doi.org\/10.1006\/mthe.1999.0019.","journal-title":"Mol Ther"},{"key":"240_CR107","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.omtm.2019.04.007","volume":"13","author":"D Israeli","year":"2019","unstructured":"Israeli D, et al. An AAV-SGCG dose-response study in a gamma-sarcoglycanopathy mouse model in the context of mechanical stress. Mol Ther Methods Clin Dev. 2019;13:494\u2013502. https:\/\/doi.org\/10.1016\/j.omtm.2019.04.007.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"240_CR108","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/brain\/awr342","volume":"135","author":"S Herson","year":"2012","unstructured":"Herson S, et al. A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain. 2012;135:483\u201392. https:\/\/doi.org\/10.1093\/brain\/awr342.","journal-title":"Brain"},{"key":"240_CR109","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"240_CR110","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"DR Asher","year":"2020","unstructured":"Asher DR, et al. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20:263\u201374. https:\/\/doi.org\/10.1080\/14712598.2020.1725469.","journal-title":"Expert Opin Biol Ther"},{"key":"240_CR111","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","volume":"4","author":"F Mingozzi","year":"2017","unstructured":"Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol. 2017;4:511\u201334. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041936.","journal-title":"Annu Rev Virol"},{"key":"240_CR112","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87\u2013104. https:\/\/doi.org\/10.1016\/j.omtm.2017.11.007.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"240_CR113","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","volume":"13","author":"JJA Lee","year":"2018","unstructured":"Lee JJA, Maruyama R, Duddy W, Sakurai H, Yokota T. Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy. Mol Ther Nucleic Acids. 2018;13:596\u2013604. https:\/\/doi.org\/10.1016\/j.omtn.2018.10.004.","journal-title":"Mol Ther Nucleic Acids"},{"key":"240_CR114","doi-asserted-by":"publisher","unstructured":"Demonbreun AR, et al. A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. Dis Model Mech. 2019;13. https:\/\/doi.org\/10.1242\/dmm.040832.","DOI":"10.1242\/dmm.040832"},{"key":"240_CR115","doi-asserted-by":"publisher","unstructured":"Wyatt EJ, et al. Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. JCI Insight. 2018;3. https:\/\/doi.org\/10.1172\/jci.insight.99357.","DOI":"10.1172\/jci.insight.99357"},{"key":"240_CR116","doi-asserted-by":"publisher","unstructured":"Selvaraj S, et al. Gene correction of LGMD2A patient-specific iPSCs for the development of targeted autologous cell therapy. Mol Ther. 2019. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.011.","DOI":"10.1016\/j.ymthe.2019.08.011"},{"key":"240_CR117","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/humc.2012.217","volume":"24","author":"F Monjaret","year":"2013","unstructured":"Monjaret F, et al. The phenotype of dysferlin-deficient mice is not rescued by adeno-associated virus-mediated transfer of anoctamin 5. Hum Gene Ther Clin Dev. 2013;24:65\u201376. https:\/\/doi.org\/10.1089\/humc.2012.217.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"240_CR118","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/mt.2012.5","volume":"20","author":"B He","year":"2012","unstructured":"He B, et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-sarcoglycan-deficient hamsters. Mol Ther. 2012;20:727\u201335. https:\/\/doi.org\/10.1038\/mt.2012.5.","journal-title":"Mol Ther"},{"key":"240_CR119","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.ymthe.2017.06.025","volume":"25","author":"LV Gushchina","year":"2017","unstructured":"Gushchina LV, et al. Treatment with recombinant human MG53 protein increases membrane integrity in a mouse model of limb girdle muscular dystrophy 2B. Mol Ther. 2017;25:2360\u201371. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.025.","journal-title":"Mol Ther"},{"key":"240_CR120","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","volume":"15","author":"ML Chu","year":"2018","unstructured":"Chu ML, Moran E. The limb-girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics. 2018;15:849\u201362. https:\/\/doi.org\/10.1007\/s13311-018-0648-x.","journal-title":"Neurotherapeutics"},{"key":"240_CR121","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1086\/342975","volume":"71","author":"DB de Bernabe","year":"2002","unstructured":"de Bernabe DB, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet. 2002;71:1033\u201343. https:\/\/doi.org\/10.1086\/342975..","journal-title":"Am J Hum Genet"},{"key":"240_CR122","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1212\/wnl.57.1.115","volume":"57","author":"YK Hayashi","year":"2001","unstructured":"Hayashi YK, et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology. 2001;57:115\u201321. https:\/\/doi.org\/10.1212\/wnl.57.1.115.","journal-title":"Neurology"},{"key":"240_CR123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jmg.2005.031963","volume":"42","author":"J van Reeuwijk","year":"2005","unstructured":"van Reeuwijk J, et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet. 2005;42:907\u201312. https:\/\/doi.org\/10.1136\/jmg.2005.031963.","journal-title":"J Med Genet"},{"key":"240_CR124","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s1534-5807(01)00070-3","volume":"1","author":"A Yoshida","year":"2001","unstructured":"Yoshida A, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell. 2001;1:717\u201324. https:\/\/doi.org\/10.1016\/s1534-5807(01)00070-3.","journal-title":"Dev Cell"},{"key":"240_CR125","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ng.2252","volume":"44","author":"T Willer","year":"2012","unstructured":"Willer T, et al. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet. 2012;44:575\u201380. https:\/\/doi.org\/10.1038\/ng.2252.","journal-title":"Nat Genet"},{"key":"240_CR126","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/ng.2253","volume":"44","author":"T Roscioli","year":"2012","unstructured":"Roscioli T, et al. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of alpha-dystroglycan. Nat Genet. 2012;44:581\u20135. https:\/\/doi.org\/10.1038\/ng.2253.","journal-title":"Nat Genet"},{"key":"240_CR127","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.1239951","volume":"341","author":"T Yoshida-Moriguchi","year":"2013","unstructured":"Yoshida-Moriguchi T, et al. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science. 2013;341:896\u20139. https:\/\/doi.org\/10.1126\/science.1239951.","journal-title":"Science"},{"key":"240_CR128","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/hmg\/ddn387","volume":"18","author":"M Kanagawa","year":"2009","unstructured":"Kanagawa M, et al. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum Mol Genet. 2009;18:621\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddn387.","journal-title":"Hum Mol Genet"},{"key":"240_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.omtm.2019.12.005","volume":"17","author":"MP Cataldi","year":"2020","unstructured":"Cataldi MP, Blaeser A, Lu P, Leroy V, Lu QL. ISPD overexpression enhances ribitol-induced glycosylation of alpha-dystroglycan in dystrophic FKRP mutant mice. Mol Ther Methods Clin Dev. 2020;17:271\u201380. https:\/\/doi.org\/10.1016\/j.omtm.2019.12.005.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"240_CR130","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1152\/jappl.2001.91.2.693","volume":"91","author":"LC Martineau","year":"2001","unstructured":"Martineau LC, Gardiner PF. Insight into skeletal muscle mechanotransduction: MAPK activation is quantitatively related to tension. J Appl Physiol (1985). 2001;91:693\u2013702. https:\/\/doi.org\/10.1152\/jappl.2001.91.2.693.","journal-title":"J Appl Physiol (1985)"},{"key":"240_CR131","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2044-5040-4-13","volume":"4","author":"C Moorwood","year":"2014","unstructured":"Moorwood C, et al. Absence of gamma-sarcoglycan alters the response of p70S6 kinase to mechanical perturbation in murine skeletal muscle. Skelet Muscle. 2014;4:13. https:\/\/doi.org\/10.1186\/2044-5040-4-13.","journal-title":"Skelet Muscle"},{"key":"240_CR132","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1152\/japplphysiol.00870.2004","volume":"98","author":"TA Hornberger","year":"2005","unstructured":"Hornberger TA, Mateja RD, Chin ER, Andrews JL, Esser KA. Aging does not alter the mechanosensitivity of the p38, p70S6k, and JNK2 signaling pathways in skeletal muscle. J Appl Physiol (1985). 2005;98:1562\u20136. https:\/\/doi.org\/10.1152\/japplphysiol.00870.2004.","journal-title":"J Appl Physiol (1985)"},{"key":"240_CR133","doi-asserted-by":"publisher","first-page":"C411","DOI":"10.1152\/ajpcell.00192.2005","volume":"290","author":"ER Barton","year":"2006","unstructured":"Barton ER. Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. Am J Physiol Cell Physiol. 2006;290:C411\u20139. https:\/\/doi.org\/10.1152\/ajpcell.00192.2005.","journal-title":"Am J Physiol Cell Physiol"},{"key":"240_CR134","doi-asserted-by":"publisher","first-page":"17263","DOI":"10.1074\/jbc.M109.063990","volume":"285","author":"ER Barton","year":"2010","unstructured":"Barton ER. Restoration of gamma-sarcoglycan localization and mechanical signal transduction are independent in murine skeletal muscle. J Biol Chem. 2010;285:17263\u201370. https:\/\/doi.org\/10.1074\/jbc.M109.063990.","journal-title":"J Biol Chem"},{"key":"240_CR135","doi-asserted-by":"publisher","first-page":"259ra144","DOI":"10.1126\/scitranslmed.3010018","volume":"6","author":"E Ceco","year":"2014","unstructured":"Ceco E, et al. Targeting latent TGFbeta release in muscular dystrophy. Sci Transl Med. 2014;6:259ra144. https:\/\/doi.org\/10.1126\/scitranslmed.3010018.","journal-title":"Sci Transl Med"},{"key":"240_CR136","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1093\/hmg\/ddv008","volume":"24","author":"JM Spinazzola","year":"2015","unstructured":"Spinazzola JM, Smith TC, Liu M, Luna EJ, Barton ER. Gamma-sarcoglycan is required for the response of archvillin to mechanical stimulation in skeletal muscle. Hum Mol Genet. 2015;24:2470\u201381. https:\/\/doi.org\/10.1093\/hmg\/ddv008.","journal-title":"Hum Mol Genet"},{"key":"240_CR137","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2044-5040-3-17","volume":"3","author":"A Muchir","year":"2013","unstructured":"Muchir A, et al. Inhibition of extracellular signal-regulated kinase 1\/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by Lamin a\/C gene mutation. Skelet Muscle. 2013;3:17. https:\/\/doi.org\/10.1186\/2044-5040-3-17.","journal-title":"Skelet Muscle"},{"key":"240_CR138","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbrc.2014.09.020","volume":"452","author":"A Muchir","year":"2014","unstructured":"Muchir A, Wu W, Sera F, Homma S, Worman HJ. Mitogen-activated protein kinase kinase 1\/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by Lamin a\/C gene mutation. Biochem Biophys Res Commun. 2014;452:958\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2014.09.020.","journal-title":"Biochem Biophys Res Commun"},{"key":"240_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddt387","volume":"23","author":"W Wu","year":"2014","unstructured":"Wu W, Iwata S, Homma S, Worman HJ, Muchir A. Depletion of extracellular signal-regulated kinase 1 in mice with cardiomyopathy caused by Lamin a\/C gene mutation partially prevents pathology before isoenzyme activation. Hum Mol Genet. 2014;23:1\u201311. https:\/\/doi.org\/10.1093\/hmg\/ddt387.","journal-title":"Hum Mol Genet"},{"key":"240_CR140","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1038\/s41467-018-05439-3","volume":"9","author":"SJ Lessard","year":"2018","unstructured":"Lessard SJ, et al. JNK regulates muscle remodeling via myostatin\/SMAD inhibition. Nat Commun. 2018;9:3030. https:\/\/doi.org\/10.1038\/s41467-018-05439-3.","journal-title":"Nat Commun"},{"key":"240_CR141","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/s0960-9822(01)00397-9","volume":"11","author":"SM Kolodziejczyk","year":"2001","unstructured":"Kolodziejczyk SM, et al. Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol. 2001;11:1278\u201382. https:\/\/doi.org\/10.1016\/s0960-9822(01)00397-9.","journal-title":"Curr Biol"},{"key":"240_CR142","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/mus.23312","volume":"46","author":"GM Smythe","year":"2012","unstructured":"Smythe GM, Forwood JK. Altered mitogen-activated protein kinase signaling in dystrophic (mdx) muscle. Muscle Nerve. 2012;46:374\u201383. https:\/\/doi.org\/10.1002\/mus.23312.","journal-title":"Muscle Nerve"},{"key":"240_CR143","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1242\/jcs.01717","volume":"118","author":"MA Griffin","year":"2005","unstructured":"Griffin MA, et al. Gamma-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion. J Cell Sci. 2005;118:1405\u201316. https:\/\/doi.org\/10.1242\/jcs.01717.","journal-title":"J Cell Sci"},{"key":"240_CR144","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/jpet.119.259663","volume":"370","author":"J Oliva","year":"2019","unstructured":"Oliva J, et al. Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy. J Pharmacol Exp Ther. 2019;370:219\u201330. https:\/\/doi.org\/10.1124\/jpet.119.259663.","journal-title":"J Pharmacol Exp Ther"},{"key":"240_CR145","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neures.2011.10.005","volume":"72","author":"N Suzuki","year":"2012","unstructured":"Suzuki N, et al. Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice. Neurosci Res. 2012;72:181\u20136. https:\/\/doi.org\/10.1016\/j.neures.2011.10.005.","journal-title":"Neurosci Res"},{"key":"240_CR146","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1172\/JCI64375","volume":"123","author":"H Shi","year":"2013","unstructured":"Shi H, et al. Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5. J Clin Invest. 2013;123:2064\u201377. https:\/\/doi.org\/10.1172\/JCI64375.","journal-title":"J Clin Invest"},{"key":"240_CR147","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1093\/hmg\/ddu270","volume":"23","author":"ER Wissing","year":"2014","unstructured":"Wissing ER, et al. P38alpha MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism. Hum Mol Genet. 2014;23:5452\u201363. https:\/\/doi.org\/10.1093\/hmg\/ddu270.","journal-title":"Hum Mol Genet"},{"key":"240_CR148","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/hmg\/ddw086","volume":"25","author":"I Kramerova","year":"2016","unstructured":"Kramerova I, et al. Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy). Hum Mol Genet. 2016;25:2194\u2013207. https:\/\/doi.org\/10.1093\/hmg\/ddw086.","journal-title":"Hum Mol Genet"},{"key":"240_CR149","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1096\/fj.03-0453com","volume":"18","author":"A Kumar","year":"2004","unstructured":"Kumar A, Khandelwal N, Malya R, Reid MB, Boriek AM. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 2004;18:102\u201313. https:\/\/doi.org\/10.1096\/fj.03-0453com.","journal-title":"FASEB J"},{"key":"240_CR150","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/hmg\/ddy349","volume":"28","author":"AH Vo","year":"2019","unstructured":"Vo AH, et al. Dusp6 is a genetic modifier of growth through enhanced ERK activity. Hum Mol Genet. 2019;28:279\u201389. https:\/\/doi.org\/10.1093\/hmg\/ddy349.","journal-title":"Hum Mol Genet"},{"key":"240_CR151","doi-asserted-by":"publisher","unstructured":"Boyer JG, et al. ERK1\/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity. JCI Insight. 2019;5. https:\/\/doi.org\/10.1172\/jci.insight.127356.","DOI":"10.1172\/jci.insight.127356"},{"key":"240_CR152","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1074\/jbc.273.3.1583","volume":"273","author":"T Yoshida","year":"1998","unstructured":"Yoshida T, Pan Y, Hanada H, Iwata Y, Shigekawa M. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J Biol Chem. 1998;273:1583\u201390.","journal-title":"J Biol Chem"},{"key":"240_CR153","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1083\/jcb.148.1.115","volume":"148","author":"TG Thompson","year":"2000","unstructured":"Thompson TG, et al. Filamin 2 (FLN2): a muscle-specific sarcoglycan interacting protein. J Cell Biol. 2000;148:115\u201326.","journal-title":"J Cell Biol"},{"key":"240_CR154","doi-asserted-by":"publisher","first-page":"10723","DOI":"10.1073\/pnas.96.19.10723","volume":"96","author":"AA Hack","year":"1999","unstructured":"Hack AA, et al. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A. 1999;96:10723\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"240_CR155","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1083\/jcb.142.5.1279","volume":"142","author":"AA Hack","year":"1998","unstructured":"Hack AA, et al. Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol. 1998;142:1279\u201387.","journal-title":"J Cell Biol"},{"key":"240_CR156","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1074\/jbc.274.7.4341","volume":"274","author":"A Cuenda","year":"1999","unstructured":"Cuenda A, Cohen P. Stress-activated protein kinase-2\/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem. 1999;274:4341\u20136. https:\/\/doi.org\/10.1074\/jbc.274.7.4341.","journal-title":"J Biol Chem"},{"key":"240_CR157","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1128\/mcb.20.11.3951-3964.2000","volume":"20","author":"Z Wu","year":"2000","unstructured":"Wu Z, et al. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol. 2000;20:3951\u201364. https:\/\/doi.org\/10.1128\/mcb.20.11.3951-3964.2000.","journal-title":"Mol Cell Biol"},{"key":"240_CR158","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s1097-2765(01)00390-2","volume":"8","author":"P Puigserver","year":"2001","unstructured":"Puigserver P, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001;8:971\u201382. https:\/\/doi.org\/10.1016\/s1097-2765(01)00390-2.","journal-title":"Mol Cell"},{"key":"240_CR159","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1093\/hmg\/dds144","volume":"21","author":"I Kramerova","year":"2012","unstructured":"Kramerova I, et al. Impaired calcium calmodulin kinase signaling and muscle adaptation response in the absence of calpain 3. Hum Mol Genet. 2012;21:3193\u2013204. https:\/\/doi.org\/10.1093\/hmg\/dds144.","journal-title":"Hum Mol Genet"},{"key":"240_CR160","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/hmg\/ddy071","volume":"27","author":"I Kramerova","year":"2018","unstructured":"Kramerova I, Torres JA, Eskin A, Nelson SF, Spencer MJ. Calpain 3 and CaMKIIbeta signaling are required to induce HSP70 necessary for adaptive muscle growth after atrophy. Hum Mol Genet. 2018;27:1642\u201353. https:\/\/doi.org\/10.1093\/hmg\/ddy071.","journal-title":"Hum Mol Genet"},{"key":"240_CR161","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13395-017-0146-6","volume":"7","author":"ME Yalvac","year":"2017","unstructured":"Yalvac ME, et al. Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis. Skelet Muscle. 2017;7:27. https:\/\/doi.org\/10.1186\/s13395-017-0146-6.","journal-title":"Skelet Muscle"},{"key":"240_CR162","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.52.1.176","volume":"52","author":"C Angelini","year":"1999","unstructured":"Angelini C, et al. The clinical spectrum of sarcoglycanopathies. Neurology. 1999;52:176\u20139.","journal-title":"Neurology"},{"key":"240_CR163","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1007\/s11033-012-1581-4","volume":"39","author":"IH Salem","year":"2012","unstructured":"Salem IH, et al. Impact of single-nucleotide polymorphisms at the TP53-binding and responsive promoter region of BCL2 gene in modulating the phenotypic variability of LGMD2C patients. Mol Biol Rep. 2012;39:7479\u201386.","journal-title":"Mol Biol Rep"},{"key":"240_CR164","doi-asserted-by":"crossref","unstructured":"Sandona, D. & Betto, R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med 11 (2009).","DOI":"10.1017\/S1462399409001203"},{"key":"240_CR165","doi-asserted-by":"publisher","first-page":"C706","DOI":"10.1152\/ajpcell.00545.2009","volume":"299","author":"B Fraysse","year":"2010","unstructured":"Fraysse B, et al. Ca2+ overload and mitochondrial permeability transition pore activation in living delta-sarcoglycan-deficient cardiomyocytes. Am J Physiol-Cell Ph. 2010;299:C706\u201313.","journal-title":"Am J Physiol-Cell Ph"},{"key":"240_CR166","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1093\/hmg\/ddp257","volume":"18","author":"I Kramerova","year":"2009","unstructured":"Kramerova I, et al. Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle. Hum Mol Genet. 2009;18:3194\u2013205. https:\/\/doi.org\/10.1093\/hmg\/ddp257.","journal-title":"Hum Mol Genet"},{"key":"240_CR167","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nm1736","volume":"14","author":"DP Millay","year":"2008","unstructured":"Millay DP, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med. 2008;14:442\u20137. https:\/\/doi.org\/10.1038\/nm1736.","journal-title":"Nat Med"},{"key":"240_CR168","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.celrep.2016.11.044","volume":"17","author":"S Pambianco","year":"2016","unstructured":"Pambianco S, et al. Reversal of defective mitochondrial biogenesis in limb-girdle muscular dystrophy 2D by independent modulation of histone and PGC-1 alpha acetylation. Cell Rep. 2016;17:3010\u201323.","journal-title":"Cell Rep"},{"key":"240_CR169","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.nmd.2016.08.008","volume":"26","author":"AE Vincent","year":"2016","unstructured":"Vincent AE, et al. Dysferlin mutations and mitochondrial dysfunction. Neuromuscul Disord. 2016;26:782\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2016.08.008.","journal-title":"Neuromuscul Disord"},{"key":"240_CR170","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1111\/febs.13098","volume":"281","author":"I Ramirez-Sanchez","year":"2014","unstructured":"Ramirez-Sanchez I, et al. (-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic delta-sarcoglycan null mouse striated muscle. FEBS J. 2014;281:5567\u201380. https:\/\/doi.org\/10.1111\/febs.13098.","journal-title":"FEBS J"},{"key":"240_CR171","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/hmg\/ddn343","volume":"18","author":"A Muchir","year":"2009","unstructured":"Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ. Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet. 2009;18:241\u20137. https:\/\/doi.org\/10.1093\/hmg\/ddn343.","journal-title":"Hum Mol Genet"},{"key":"240_CR172","doi-asserted-by":"publisher","first-page":"e005418","DOI":"10.1161\/CIRCHEARTFAILURE.118.005418","volume":"12","author":"H Kanamori","year":"2019","unstructured":"Kanamori H, et al. Metformin enhances autophagy and provides cardioprotection in delta-sarcoglycan deficiency-induced dilated cardiomyopathy. Circ Heart Fail. 2019;12:e005418. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005418.","journal-title":"Circ Heart Fail"},{"key":"240_CR173","doi-asserted-by":"publisher","first-page":"e005873","DOI":"10.1161\/CIRCHEARTFAILURE.119.005873","volume":"12","author":"DW Hammers","year":"2019","unstructured":"Hammers DW. RevAMP(K)ing mitochondria for sarcoglycanopathy therapeutics. Circ Heart Fail. 2019;12:e005873. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.005873.","journal-title":"Circ Heart Fail"},{"key":"240_CR174","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/bjp.2008.285","volume":"155","author":"J Reutenauer","year":"2008","unstructured":"Reutenauer J, Dorchies OM, Patthey-Vuadens O, Vuagniaux G, Ruegg UT. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol. 2008;155:574\u201384. https:\/\/doi.org\/10.1038\/bjp.2008.285.","journal-title":"Br J Pharmacol"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-020-00240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-020-00240-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-020-00240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T23:45:50Z","timestamp":1627515950000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-020-00240-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":174,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1186\/s13395-020-00240-7","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PBK consults for AveXis, receives honoraria from Wiley for serving as associate editor of <i>Muscle & Nerve<\/i>, and receives royalties from Wolters Kluwer for authoring topics for <i>UpToDate<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}